Search Results

Stealth BioTherapeutics Inc. announced today the presentation of new SBT-589 data demonstrating cardioprotective effects across pre-clinical models of Friedreich’s ataxia (FA).

Innovent Biologics, Inc. announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor, were published in the Journal of Clinical Oncology and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting.

Innovent Biologics, Inc. announced that results from the pivotal Phase 2 TRUST-I study conducted in China evaluating taletrectinib, next-generation ROS1 tyrosine kinase inhibitor, were published in the Journal of Clinical Oncology and will be highlighted in an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting.

Immunis, Inc., a private biotech company revolutionizing cellular secretome therapeutics, is proud to announce that its Chairman, Dr. Hans Keirstead, will present at the exclusive 13D Brain Trust Conference in the Bahamas.

Omeros Corporation announced the sale to DRI Healthcare Acquisitions LP, a wholly owned subsidiary of DRI Healthcare Trust, of an expanded interest in certain royalty payments based on net sales of OMIDRIA in the United States.

Brain Trust Bio, a leader in treatment development for central nervous system diseases, has received approval to commence Phase I clinical trials in Australia for its Continuous Intrathecal Drug Delivery Method.